<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article60</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/ORIGIN_n-3_Fatty_Acids" style="display:block; margin-bottom:10px;">ORIGIN n-3 Fatty Acids Original</a></li>
<h2><strong>ORIGIN n-3 Fatty Acids</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "N-3 Fatty Acids in High-Risk Patients with Dysglycemia". The New England Journal of Medicine. 2012. 367(4):309-318. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In high-risk patients with dysglycemia, does daily supplementation with n-3 fatty acids reduce the rate of cardiovascular events?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in high-risk patients with dysglycemia.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Patients with type 2 diabetes or at high risk for diabetes are at an increased risk of cardiovascular events. Previous studies have suggested that n-3 fatty acids may have cardiovascular benefits, but evidence in patients with dysglycemia has been limited.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
At the time of the study publication, the usage of n-3 fatty acids for the reduction of cardiovascular events in high-risk patients with dysglycemia was not established in guidelines.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, parallel-group, randomized, placebo-controlled trial<br/>
- N=12,536<br/>
- Interventions: 1 g capsule of at least 900 mg (90% or more) ethyl esters of n-3 fatty acids (n=6,281) or placebo (n=6,255)<br/>
- Median follow-up: 6.2 years<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion Criteria: Patients ≥50 years old with impaired fasting glucose, impaired glucose tolerance, or diabetes at high risk for cardiovascular events<br/>
- Exclusion Criteria: Unwillingness to discontinue non-study n-3 supplements, HbA1c ≥9%, recent CABG without subsequent cardiovascular event, severe heart failure, active cancer affecting survival<br/>
- Baseline Characteristics: Mean age 64 years, 65% men, 59% had previous myocardial infarction, stroke, or revascularization<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- 1 g capsule of n-3 fatty acids daily containing 465 mg of EPA and 375 mg of DHA<br/>
- Placebo capsule containing approximately 1 g of olive oil<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
- Death from cardiovascular causes: 9.1% in n-3 fatty acids group vs. 9.3% in placebo group (HR 0.98; 95% CI, 0.87 to 1.10; P=0.72)<br/>
<br/>
Secondary Outcomes<br/>
- Major vascular events: 16.5% vs. 16.3% (HR 1.01; 95% CI, 0.93 to 1.10; P=0.81)<br/>
- Death from any cause: 15.1% vs. 15.4% (HR 0.98; 95% CI, 0.89 to 1.07; P=0.63)<br/>
- Death from arrhythmia: 4.6% vs. 4.1% (HR 1.10; 95% CI, 0.93 to 1.30; P=0.26)<br/>
- Triglyceride levels reduced by 14.5 mg per deciliter more in n-3 fatty acids group (P&lt;0.001)<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The daily dose of n-3 fatty acids may have been too low to demonstrate a benefit.<br/>
- Assessment of the effect of n–3 fatty acids based on dietary intake was conducted through a questionnaire rather than serum level measurement.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Funded by Sanofi, with study drugs provided by Pronova BioPharma Norge.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Gerstein H. C. et al. "Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia." The New England Journal of Medicine, 2012.<br/>
- Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial investigators at NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
